Balloon‐Expandable Myval Octacor Versus Self‐Expanding Evolut PRO/PRO+ and Acurate Neo2: Short‐Term Outcomes From Propensity‐Matched Analysis
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.70097 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Elisabetta Moscarella und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Aortic Valve, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
With transcatheter aortic valve implantation (TAVI) now extending to lower‐risk and younger patients, optimizing procedural and hemodynamic outcomes is critical. The Myval Octacor, a new balloon‐expandable valve (BEV), was developed to improve outcomes by reducing paravalvular regurgitation (PVL), minimizing pacemaker implantation (PPI) rates, and enhancing hemodynamic performance. However, limited data are available comparing Myval Octacor to contemporary self‐expanding supra‐annular valves (SEVs) Evolut PRO/PRO+ and Acurate Neo2.
Aims
This study aimed to compare the safety, efficacy, and short‐term clinical outcomes of Myval Octacor with SEVs in transfemoral TAVI patients.
Methods
We conducted a prospective, multicenter registry including patients treated with Myval Octacor, then compared them to SEV recipients from the NEOPRO2 registry. Propensity score matching adjusted for baseline differences between groups. The primary endpoint was 30‐day Valve Academic Research Consortium‐3 (VARC‐3) device success. Secondary endpoints included technical success, valve performance, and early safety outcomes.
Results
Among 252 Myval Octacor patients and 2175 SEV patients, 90 matched pairs were compared. Myval Octacor patients showed higher 30‐day VARC‐3 device success than SEVs patients (97% vs. 88%, p = 0.024), primarily due to a numerically lower rate of moderate‐to‐severe PVL (1% vs. 7%, p = 0.06). The Octacor group also exhibited larger indexed effective orifice areas. Mortality, stroke, PPI, and myocardial infarction rates were similar between groups at 30 days.
Conclusions
The Myval Octacor demonstrated comparable early safety and efficacy to supra‐annular SEVs, with advantages in device success rate and hemodynamic performance. Adequately sized randomized study is required to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
- Division of Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, Italy.
- IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
- Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.
- University of Catania, Catania, Italy.
- Pineta Grande, Castel Volturno, Italy.
ORCID-Profile: Elisabetta Moscarella, Won-Keun Kim, Rodolfo Caminiti, Marco Barbanti, Luca Testa, Rodrigo Estévez-Loureiro, Nikolay Stoyanov, Antonio Mangieri, Andrea Scotti, Azeem Latib
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Moscarella, E., Ielasi, A., Kim, W. K., Caminiti, R., Barbanti, M., Giordano, A., Holzamer, A., Testa, L., Adamo, M., Eitan, A., Estévez-Loureiro, R., Farkic, M., Stoyanov, N., Leick, J., Kovacevic, M., Tigges, E., Mangieri, A., Scotti, A., & Latib, A. (2025). Balloon‐Expandable Myval Octacor Versus Self‐Expanding Evolut PRO/PRO+ and Acurate Neo2: Short‐Term Outcomes From Propensity‐Matched Analysis. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70097
Vancouver
Moscarella E, Ielasi A, Kim WK, Caminiti R, Barbanti M, Giordano A, et al. Balloon‐Expandable Myval Octacor Versus Self‐Expanding Evolut PRO/PRO+ and Acurate Neo2: Short‐Term Outcomes From Propensity‐Matched Analysis. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70097
BibTeX
@article{Moscarella2025,
author = {Moscarella, Elisabetta and Ielasi, Alfonso and Kim, Won-Keun and Caminiti, Rodolfo and Barbanti, Marco and Giordano, Arturo and Holzamer, Andreas and Testa, Luca and Adamo, Marianna and Eitan, Amnon and Estévez-Loureiro, Rodrigo and Farkic, Mihajlo and Stoyanov, Nikolay and Leick, Juergen and Kovacevic, Mila and Tigges, Eike and Mangieri, Antonio and Scotti, Andrea and Latib, Azeem},
title = {Balloon‐Expandable Myval Octacor Versus Self‐Expanding Evolut PRO/PRO+ and Acurate Neo2: Short‐Term Outcomes From Propensity‐Matched Analysis},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.70097}
}
EUVIMED